1. Policy of the Journal

1.1. Scope
Clinical Science publishes papers in the field of clinical investigation, provided they are of a suitable standard and contribute to the advancement of knowledge in this field. The term 'clinical investigation' is used in its broad sense to include studies in animals and the whole range of biochemical, physiological, immunological and other approaches that may have relevance to disease in man. Studies which are confined to normal subjects, or animals, or are purely methodological in nature may be acceptable. The material presented should permit conclusions to be drawn and should not be only of a preliminary nature. The journal publishes four types of manuscript, namely invited Editorial Reviews, Full Papers, Short Communications and Correspondence. In addition, Clinical Science publishes abstracts of the proceedings of the Medical Research Society and also that Society's Annual Guest Lecture.

1.2. The Editorial Board
The Board comprises Editors for the Medical Research Society and the Biochemical Society and a Chairman and Deputy Chairman who are drawn alternately from the two Societies. Members of the Board retire after a maximum of 5 years; the Chairman serves in his capacity for 2 years. The membership of the Board is designed to cover as wide a range of interests as possible.

The main function of the Board is to decide on the acceptability of submitted papers, but it also deals with general matters of editorial policy. Financial policy is dealt with separately by the Committee of Management.

1.3. The editorial process
A submitted paper is first read by the Chairman of the Editorial Board who then sends it to an Editor. The latter considers the paper in detail and sends it to one or more referees (who remain anonymous) from outside the membership of the Board. The Editor returns it with his recommendation to the Chairman who then writes formally to
the authors. The ultimate responsibility of acceptance for publication lies with the Chairman. If the Chairman is for any reason unavailable, the Deputy Chairman assumes this function.

1.4. Ethics of investigations on human subjects

Authors must state in the text of their paper the manner in which they have complied, where necessary, with the recommendations on human investigations published in the Medical Research Council report of 1962/63 [British Medical Journal (1964) ii, 178–180]. Consent must be obtained from each patient or subject after full explanation of the purpose, nature and risks of all procedures used and the fact that such consent has been given should be recorded in the paper. Papers should also state that the Ethical Committee of the Institution in which the work was performed has given approval to the protocol. The Editorial Board will not accept papers the ethical aspects of which are, in the Board’s opinion, open to doubt.

1.5. Originality of papers

Submission of a paper to the Editorial Board is taken to imply that it reports unpublished work, that it is not under consideration for publication elsewhere and that, if accepted for publication by Clinical Science, it will not be published elsewhere in the same form, either in English or in any other language, without the consent of the Editorial Board. This does not usually apply to previous publication of oral communications in brief abstract form. In such cases authors should enclose copies of the abstracts. When a paper has been accepted for publication the author, or in the case of multiple authorship the author with whom correspondence has taken place, will be asked to sign a statement vesting the copyright in the Editorial Board. This is particularly important in relation to methodology.

Where the reader is referred to previous works by the same author(s) for important details relevant to the present work, it often speeds up assessment if reprints are enclosed with the typescript. This is of particular importance in relation to methodology.

The dates of receipt and acceptance of the paper will be published. If the paper has to be returned to the authors for revision and is not resubmitted within 1 month, the date of receipt will be revised accordingly. For Short Communications the published date will always be that of receipt of the final version. It is emphasized that badly presented or unduly long papers will be returned for revision and delays in publication will be inevitable. Similar delays will be incurred if the typescript is not prepared strictly in accordance with the instructions detailed below.

2. SUBMISSION OF MANUSCRIPTS:
GENERAL INFORMATION
AND FORMAT

2.1. General

Papers submitted for publication should be sent to the Chairman of the Editorial Board (Dr D. J. Galton, Department of Medicine, St Bartholomew’s Hospital, West Smithfield, London EC1M 6BQ).

The submission should contain three copies (of which two may be photocopies) of the typescript, Tables, Figures etc. The authors should retain one copy of the paper. The Editorial Board does not accept responsibility for damage or loss of papers submitted, although great care is taken to ensure safety and confidentiality of the typescript during the editorial process. In the case of multiple authorship, the covering letter should indicate that the approval of all co-authors has been obtained.

Papers should be presented so that they are intelligible to the non-specialist reader of the journal. This is particularly important in highly specialized fields and a very brief résumé of the current state of knowledge is usually helpful. Certain types of material, e.g. mathematical formulations requiring more than trivial derivations, should be given in a separate Appendix.

2.2. Full papers

The authors should refer to a current issue of Clinical Science to make themselves familiar with the general layout. Concise presentation is very important for rising costs are a severe constraint on space. The length of manuscript and the number of Figures and Tables must be kept to a minimum. Extensive Tables of data can be deposited with the Royal Society of Medicine (see 2.5). Guidance for Authors is usually published in the January issue of the journal, and revised periodically.

Typescripts should be, in general, arranged as follows:

(a) Title page. Title: this should be as informative as possible, since titles of papers are being increasingly used in indexing and coding for information storage and retrieval. The title should indicate the species in which the observations reported have been made. The numbering of parts in a series of papers is not permitted.
List of authors' names (degrees and appoint-
ments are not required).
Laboratory or Institute of origin.
Key words: for indexing the subject of the paper; they should, if possible, be selected from the current issues of 'Medical Subject Headings' (MeSH), produced by the Index Medicus.
Short title: for use as a running heading in the printed text; it should not exceed forty-five characters and spaces.
Author for correspondence: the name and address of the author to whom queries and requests for reprints should be sent.
(b) Summary. This should be a brief statement arranged in numbered paragraphs of what was done, what was found and what was concluded and should rarely exceed 250 words. Contributors from non-English speaking countries are invited to include a translation of the summary in their own language. Abbreviations should be avoided as far as possible and must be defined. Statistical and methodological details including exact doses should also be avoided unless they are essential to the understanding of the summary.
(c) Introduction. This should contain a clear statement of the reason for doing the work, but should not include either the findings or the conclusions.
(d) Methods. The aim should be to give sufficient information in the text or by reference to permit the work to be repeated without the need to communicate with the author.
(e) Results. This section should not include material appropriate to the Discussion section.
(f) Discussion. This should not contain results and should be pertinent to the data presented.
(g) Acknowledgments. These should be as brief as possible.
(h) References. See p. v for the correct format.
(i) Figures and Tables. See p. iv.

2.3. Short Communications
The Short Communication should describe completed work, and should not be merely a preliminary communication. The format of Short Communications should be similar to that of Full Papers, but should not exceed 1200 words of text. One Figure or Table is allowed, but if neither is included the text may be expanded to 1400 words. The passage of Short Communications through the editorial process can frequently be expedited and contributors are encouraged to take advantage of these facilities when rapid publication is of importance and the material can be presented concisely. The paper should appear in print within 3 months of acceptance. When submitting Short Communications, authors should make it quite clear that the work is intended to be treated as a Short Communication.

2.4. Correspondence
Letters containing critical assessments of material published in Clinical Science, including Editorial Reviews, will be considered for the Correspondence section of the journal. Such letters should be sent to the Chairman of the Editorial Board within 6 months of the appearance of the article concerned. They will be sent to the authors for comment and both the letter and any reply by the author will be published together. Further correspondence arising therefrom will also be considered for publication. Consideration will also be given to publication of letters on ethical matters.

2.5. Arrangements for large amounts of information
It is impracticable to publish very large sets of individual values or very large numbers of diagrams, and under these circumstances a summary of the information only should be included in the paper. The information from which the summary was derived should be submitted with the typescript and, if the latter is accepted, the Editors may ask for a copy of the full information and diagrams to be deposited with the Librarian, the Royal Society of Medicine, 1 Wimpole Street, London W1M 8AE, who will issue copies on request. Experience has shown that such requests are frequently received.

2.6. Proof corrections
These are expensive and corrections of other than printers' errors may have to be charged to the author.

2.7. Offprints
Fifty offprints are supplied free and additional copies may be obtained at terms, based upon the cost of production, that will be given with the proofs. All offprints should be ordered when the proofs are returned.

2.8. Availability on MEDLINE
Summaries of papers in Clinical Science are available on-line on teleprinters participating in the MEDLINE system run by the National Library of Medicine, National Institutes of Health, Bethesda, Maryland, U.S.A.
3. MISCELLANEOUS NOTES

3.1. Abbreviations
Abbreviations should be avoided; if used they must be defined at the first mention; new abbreviations should be coined only for unwieldy names which occur frequently. Abbreviations should not appear in the title nor, if possible, in the Summary. A list of accepted abbreviations is on p. vi. Numbers, not initials, should be used for patients and subjects.

3.2. Anatomical nomenclature
This should follow the recommendations of the International Anatomical Nomenclature Committee (1966) Nomina Anatomica, 3rd edn, Excerpta Medica Foundation, Amsterdam.

3.3. Animals, plants and micro-organisms
The full binomial specific names should be given at first mention for all experimental animals other than common laboratory animals. The strain and, if possible, the source of laboratory animals should be stated. Thereafter in the text, single letter abbreviations may be given for the genus; if two genera with the same initial letter are studied, abbreviations such as Staph. and Strep. should be used.

3.4. Buffers and salts
The acidic and basic components should be given, together with the pH. Alternatively, a reference to the composition of the buffer should be given. Further details are provided in the Biochemical Journal (1978) 169,9.

When describing solutions containing organic anions and their parent acids, the salt designator (e.g. lactate, urate, oxalate) should be used in preference to the name of the acid (lactic, uric, oxalic) unless it is certain that virtually all of the acid is in the undissociated form.

The composition of incubation media should be described, or a reference to the composition should be given.

3.5. Doses
Doses of drugs should be expressed in mass terms, e.g. milligrams (mg) or grams (g), and also (in parentheses) in molar terms, e.g. mmol, mol, where this appears to be relevant. Molecular weights of many drugs may be found in The Merck Index, 8th edn, Merck and Co. Inc., N.J., U.S.A.

3.6. Enzymes
Nomenclature should follow that given in Enzyme Nomenclature (1978), Academic Press, London and New York, and Enzyme Commission (EC) number should be quoted at the first mention. Where an enzyme has a commonly used informal name, this may be employed after the first formal identification. A unit of enzyme activity should preferably be expressed as that amount of material which will catalyse transformation of 1 μmol of the substrate/min under defined conditions, including temperature and pH. Alternatively, or when the natural substrate has not been fully defined, activity should be expressed in terms of units of activity relative to that of a recognized reference preparation, assayed under identical conditions. Activities of enzymes should normally be expressed as units/ml or units/mg of protein.

3.7. Evaluation of measurement procedures
When a new measuring procedure has been used, or when an established procedure has been applied in a novel fashion, an estimate of the precision of the procedure should be given. This should, as far as possible, indicate what sources of variation have been included in this estimate, e.g. variation of immediate replication, variation within different times of day, or from day to day etc.

If the precision of measurement varies in proportion to the magnitude of the values obtained, it can best be expressed as the coefficient of variation; otherwise it should be expressed by an estimate of the (constant) standard error of a single observation, or by estimates at several points within the range of observed values.

When recovery experiments are described the approximate ratio of the amount added to the amount already present and the stage of the procedure at which the addition was made should be stated.

3.8. Figures and Tables
These are expensive to print and their number should be kept to a minimum. Their appropriate position in the paper should be indicated in the margin of the text. References to Figures and Tables should be in Arabic numerals, e.g. Fig. 3, and they should be numbered in order of appearance. In general, the same data should not be presented in both a Figure and a Table.

Figures, with captions attached, should be supplied as original drawings or matt photographs together with photocopies. All Figures should have their number and the authors' names written in pencil on the back; the top of the Figure should be indicated with a pencilled arrow. A horizontal or square layout is preferred to a vertical one. Acceptable symbols for experimental points are •, 
The symbols $\times$ or $+$ must be avoided. The same symbols must not be used for two curves where the points might be confused. For scatter diagrams, solid symbols are preferred. When a particular variable appears in more than one Figure, the same symbol should be used for it throughout, if possible.

Curves should not be drawn beyond the experimental points, nor should axes extend appreciably beyond the data. Only essential information that cannot readily be included in the legend should be written within the Figure.

Figures for half-tone reproduction should be submitted as glossy prints. They are particularly expensive to print and their use should be avoided as far as possible.

Tables should be typed separately from the text. They should have an underlined title followed by any legend.

Captions for the Figures, and titles and legends for the Tables, should make them readily understandable without reference to the text. Adequate statistical information, including that on regression lines, should be included in Figure captions where appropriate.

3.9. Footnotes

These should be avoided as far as possible but where they are used in Tables they should be identified by the symbols * † ‡ § ¶, in that order.

3.10. Isotope measurements

The information given should include (a) conditions of radioactivity counting, e.g. infinitely thick, infinitely thin; (b) the nature of the phosphor used in liquid-scintillation counting; (c) details of corrections made to the observed count rate, e.g. for ‘quenching’ or ‘cross-over’; (d) standard deviation of the results or a statement of the minimum total counts above background collected and the background value.

In general the specific radioactivity of the starting materials should be given, preferably in terms of radioactivity per unit weight or, for stable isotopes, as atoms % excess.

Pending the general introduction of SI units radioactivity should continue to be expressed in terms of the curie (Ci) followed by the corresponding figure in terms of the becquerel (Bq: disintegrations/s), in parentheses, and suitably rounded.

3.11. Radionuclide applications in man

If new or modified radionuclide applications in man are described, an estimate of the maximal possible radiation dose to the body and critical organs should be given.

For the time being this can continue to be expressed in rems, but with the corresponding figure in sieverts (Sv) given in parentheses after it.

3.12. Methods

In describing certain techniques, namely centrifugation (when the conditions are critical), chromatography and electrophoresis, authors should follow the recommendations published by the Biochemical Society (currently, Biochemical Journal (1978) 169, 1–21).

3.13. Nomenclature of disease

This should follow the International Classification of Disease (8th revision, World Health Organization, Geneva, 1969) as far as possible.


Care is needed where powers are used in Table headings and in Figures to avoid numbers with an inconvenient number of digits. For example: (i) an entry ‘2’ under the heading $10^2k$ means that the value of $k$ is 0.002; an entry ‘2’ under the heading $10^{-2}k$ means that the value of $k$ is 2000. (ii) A concentration 0-00015 mol/l may be expressed as 15 under the heading ‘conc. (mmol/l)’ or as 150 under the heading ‘conc. (mol/l)’ or as 15 under the heading ‘$10^4$ x concn. (mol/l)’, but not as 15 under the heading ‘conc. (mol/l $\times 10^{-9}$)’.

3.15. References

These should be in alphabetical order of first authors. The full title of the paper, the journal and the first and last page numbers should be given, e.g.


When the quotation is from a book, the following format should be used, giving the relevant page or chapter number:


References in the text should follow the style: Clark, Freedman, Campbell & Winn (1969) on the first quotation and, if there are more than two authors, ‘Clark et al. (1969)’ or ‘(Clark et al., 1969)’ in subsequent quotations.

References to ‘personal communications’ and ‘unpublished work’ should appear in the text only and not in the list of references. The name and
initials of the source of information should be given. When the reference is to material that has been accepted for publication but has not yet been published, this should be indicated in the list of references by 'In press' together with the name of the relevant journal and, if possible, the expected date of publication. If such a citation is of major relevance to the manuscript submitted for publication authors are advised that the editorial process might be expedited by the inclusion of a copy of such work. In the case of quotations from personal communications the authors should state in the covering letter that permission for quotation has been obtained.

3.16. Solutions
Concentration of solutions should be described where possible in molar terms (mol/l and subunits thereof), stating the molecular particle weight if necessary. Values should not be expressed in terms of normality or equivalents. Mass concentration should be expressed as g/l or subunits thereof, for example mg/l or μg/l. For solutions of salts, molar concentration is always preferred to avoid ambiguity as to whether anhydrous or hydrated compounds are used. Concentrations of aqueous solutions should be given as mol/l or mol/kg (g/l or g/kg if not expressed in molar terms) rather than % (w/v) or % (w/w). It should always be made clear whether concentrations of components in a reaction mixture are final concentrations or the concentrations in solutions added.

3.17. Spectrophotometric data
The term 'absorbance' [log (I₀/I)] should be used rather than 'optical density' or 'extinction'. The solvent, if other than water, should be specified. Symbols used are: A, absorbance; a, specific absorption coefficient (litre g⁻¹ cm⁻¹) (alternatively use A₁%cm⁻¹); ε, molar absorption coefficient (the absorbance of a molar solution in a 1 cm light-path) (litre mol⁻¹ cm⁻¹, not cm² mol⁻¹).

3.18. Spelling

3.19. Statistics
Papers are frequently returned for revision (and their publication consequently delayed) because the authors use inappropriate statistical methods. Two common errors are the use of means, standard deviations and standard errors in the description and interpretation of grossly non-normally distributed data and the application of t-tests for the significance of difference between means in similar circumstances, or when the variances of the two groups are non-homogeneous. In some circumstances it may be more appropriate to provide a 'scattergram' than a statistical summary.

A reference should be given for all methods used to assess the probability of a result being due to chance. The format for expressing mean values and standard deviations or standard errors of the mean is, for example: mean cardiac output 10.4 l/min (sd 1.2; n = 11). Degrees of freedom should be indicated where appropriate. Levels of significance are expressed in the form P < 0.01.

3.20. Trade names
The name and address of the supplier of special apparatus and of biochemicals should be given. In the case of drugs, approved names should always be given with trade names and manufacturers in parentheses.

3.21. Computer modelling
Papers concerned primarily with computer modelling techniques are acceptable provided that use of such techniques leads to a clear choice between two or more alternative hypotheses, or to the formulation of a new hypothesis amenable to experimental challenge or verification, or provides some new insight into the behaviour of a particular physiological system. Extensive technical details of hardware and software should not be given.

4. UNITS: THE SI SYSTEM

The recommended Système International (SI) units [see Quantities, Units and Symbols, 2nd edn (1975) The Royal Society, London] are used by Clinical Science. All papers submitted should use these units except for blood pressure values, which should be expressed in mmHg, or gas tensions, where values at the author's discretion may be given as mmHg (with kPa in parentheses) or as kPa (with mmHg in parentheses) in the text and either as mmHg or as kPa in Figures, which (if practicable) should have scales in both units. Airways pressure should be expressed in kPa. Where molecular weight is known, the amount of a chemical or drug should be expressed in mol or in an appropriate subunit, e.g. mmol. Energy should be expressed in joules (J).
The basic SI units and their symbols are as follows:

<table>
<thead>
<tr>
<th>Physical quantity</th>
<th>Name</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>length</td>
<td>metre</td>
<td>m</td>
</tr>
<tr>
<td>mass</td>
<td>kilogram</td>
<td>kg</td>
</tr>
<tr>
<td>time</td>
<td>second</td>
<td>s</td>
</tr>
<tr>
<td>electric current</td>
<td>ampere</td>
<td>A</td>
</tr>
<tr>
<td>thermodynamic temperature</td>
<td>kelvin</td>
<td>K</td>
</tr>
<tr>
<td>luminous intensity</td>
<td>candela</td>
<td>cd</td>
</tr>
<tr>
<td>amounts of substance</td>
<td>mole</td>
<td>mol</td>
</tr>
</tbody>
</table>

The following are examples of derived SI units:

<table>
<thead>
<tr>
<th>Physical quantity</th>
<th>Name</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>length</td>
<td>metre</td>
<td>m</td>
</tr>
<tr>
<td>mass</td>
<td>kilogram</td>
<td>kg</td>
</tr>
<tr>
<td>electric current</td>
<td>ampere</td>
<td>A</td>
</tr>
<tr>
<td>thermodynamic</td>
<td>kelvin</td>
<td>K</td>
</tr>
<tr>
<td>luminous intensity</td>
<td>candela</td>
<td>cd</td>
</tr>
<tr>
<td>amounts of substance</td>
<td>mole</td>
<td>mol</td>
</tr>
</tbody>
</table>

The following are examples of derived SI units:

<table>
<thead>
<tr>
<th>Physical quantity</th>
<th>Name</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>energy</td>
<td>joule</td>
<td>J</td>
</tr>
<tr>
<td>force</td>
<td>newton</td>
<td>N</td>
</tr>
<tr>
<td>power</td>
<td>watt</td>
<td>W</td>
</tr>
<tr>
<td>pressure</td>
<td>pascal</td>
<td>Pa</td>
</tr>
<tr>
<td>electric charge</td>
<td>coulomb</td>
<td>C</td>
</tr>
<tr>
<td>electric potential</td>
<td>volt</td>
<td>V</td>
</tr>
<tr>
<td>resistance</td>
<td>ohm</td>
<td>Ω</td>
</tr>
<tr>
<td>conductance</td>
<td>siemens</td>
<td>S</td>
</tr>
<tr>
<td>capacitance</td>
<td>farad</td>
<td>F</td>
</tr>
<tr>
<td>frequency</td>
<td>hertz</td>
<td>Hz</td>
</tr>
<tr>
<td>volume</td>
<td>litre</td>
<td>l</td>
</tr>
</tbody>
</table>

Note: Avoid using compound prefixes unless necessary.

Notes:

(i) Full stops are not used after symbols.

(ii) Minutes (min), hours (h), days and years will continue to be used in addition to the SI unit of time (the second (s)).

(iii) The solidus may be used in a unit as long as it does not have to be employed more than once, e.g. mmol/l is acceptable, but ml/min/kg is not, and should be replaced by ml min⁻¹ kg⁻¹.
British Pharmacopoeia
calculated
'Calorie' (= 1000 cal)
carbon dioxide output (in respiratory physiology)
cardiac frequency
cardiac output
centimetre
clearance of x coenzyme A and its acyl derivatives
compare
complement fractions
compliance (respiratory physiology)
concentrated
concentration
conductance (respiratory physiology)
correlation coefficient
counts/min, counts/s
cubic centimetres
curie
cycle/s
cysteine
dates
dead-space minute ventilation
dead-space volume
degrees, Celsius or centigrade
dehydrated coenzyme A
dehydrated cysteine
dehydrated diethylenetriamine
dehydrated dialysate
diffusion coefficient
differential of x with respect to time
dilute
2,3-diphasphoglycerate
direct current
disintegration/min
disintegration/s
dissociation constant
acidic
basic
apparent
minus log of
doses

dyne
electrocardiogram
electroencephalogram

guidance for authors
write in full and give edition
calc. (in Tables only) not used; recalculate as kilojoules (1 'Calorie' = 4.184 kJ)
Vco2; express in ml STP/min
f; in beats/min express in 1/min
C
C
Cl
CoA and acyl-CoA
cf.
c; express in 1 kPa⁻¹
conc.
concn.; may be denoted [ ]; e.g. plasma [HCO3⁻]
G; express in 1 s⁻¹ kPa⁻¹
r; may be used without definition
c.p.m., c.p.s.
use ml
CI (1 CI = 3.7 × 10⁻¹⁰
d.p.s.)
Hz
Cys
e.g. 11 August 1970
Vd
V
oC
not deoxy
DOC
DOCA
DNA
diffusate preferred; 'dialysate' should be clearly defined
DEAE-cellulose
x (= dx/dt)
1,25-(OH)₂D₃
dil.
2,3-DPG
d.c.
d.p.m.
d.p.s.
K
K
e.g. K
pK
avoid Latin designations such as b.d. and t.d.
not used; express in newtons (1 dyne = 10⁻⁵ N)
E; express in Pa m⁻³
ECG
EEG
electromotive force
electron spin resonance
electronvolt
equation
equivalents (amount of a chemical)
erthrocyte count
erthrocyte sedimentation rate
ethanol, ethanolic
ethylene diamine tetra-acetate
exchangeable
Experiment (with reference numeral)
expired minute ventilation
extinction
extracellular fluid
extracellular fluid volume
extraction ratio of x (renal)
filtered load of x (renal)
follicle-stimulating hormone
forced expiratory volume in 1-0 s
fractional concentration in dry gas
fractional disappearance rate
frequency of respiration
functional residual capacity
gas–liquid chromatography
gas transfer factor
glomerular filtration rate
glutamic acid
glutamine
glutathione
glycine
gram
gravitational field, unit of (9.81 m s⁻²)
growth hormone
haematocrit
haemoglobin
half-life
histidine
hour
human chorionic gonadotropin
human placental lactogen
hydrocortisone
hydrogen ion activity
minus log of
25-hydroxycholecalciferol
hydroxyproline
immunoglobulins
e.m.f.
e.s.r.
eV (for radiation energies)
eqn.
not used; recalculate in molar terms
express as 10¹² cells/l
ESR
not ethyl alcohol or alcoholic
EDTA
Na⁺, K⁺ etc., for total exchangeable sodium, potassium etc.
Expt.; plural, Expts.
V
use absorbance
ECF
ECFV
E
Fig.; plural, Figs.
F
FSH
FEV₁₀
k (as in A = Ate⁻kt)
f; in breaths/min
FRC
g.l.c.
T; in mmol min⁻¹ kPa⁻¹
GFR
Glu
Gln
GSH (reduced); GSSG (oxidized)
Gly
g
GH; if human, HGH
not allowed; use packed cell volume (PCV)
Hb; express in g/dl
h
HCG
HPL
use cortisol
aH; express in nmol/l
pH
25-(OH)D₃
Hyp
IgA, IgD, IgE, IgG, IgM
injection routes:
- intra-arterial
- intramuscular
- intraperitoneal
- intravenous
- subcutaneous
- international unit

Guidance
- Use abbreviations only in Figures
- i.a.
- i.m.
- i.p.
- i.v.
- s.c.
- i.u. (definition and reference should be given for uncommon or ambiguous applications, e.g. enzymes)

intracellular fluid
- intracellular fluid volume
- ionic strength
- isoleucine
- isotonic

isotopically labelled compounds
- [U-14Clglucose,
- [1-14Clglucose,
- sodium [1-14Clacetate;
- use [1-14Clalbumin, not [14Cl]albumin
for simple molecules:
- [1-14CO2, [2H2O

joule
- kilogram(me)
- kilopond

lactate dehydrogenase
- leucine
- leucocyte count
- lipoproteins (serum)

high density
- low density
- very low density

litre

logarithm (base 10)
- logarithm (base e)
- lysine
- maximum

mean corpuscular haemoglobin

mean corpuscular haemoglobin concentration

mean corpuscular volume

median lethal dose
- meta-
- melting point
- methanol, methanolic
- methionine
- metre

Michaelis constant
- micromole
- micron (10^-6 m)
- milliequivalent

millilitre

millimetre of mercury
- mmHg; for blood pressure and, at authors' discretion, for gas tensions: see p. vi (1 mmHg = 0.133 kPa)

millimolar (concentration)

millimole

minimum

minute (60 s)

molar

molar concentration

molar absorption coefficient

mole

molecular weight

nicotinamide-adenine dinucleotide

nicotinamide-adenine dinucleotide phosphate

normal

normal temperature and pressure

nuclear magnetic resonance number (in enumerations)

observed

ohm

ornithine

orthophosphate (inorganic)

osmolality

oxygen uptake per minute

(par in respiratory physiology)

packed cell volume

page, pages

para-

para-aminomethylphosphorurate

partial pressure

e.g. alveolar, of O2

arterial, of CO2

capillary, of O2

mixed venous, of CO2

pascal

per

per cent

petroleum ether

phenylalanine

plasma renin activity

plasma volume

poise

Phe

express as pmol of angiotensin I h^-1 ml^-1

PV

1 poise = 10^-1 N s m^-2
potential difference
power output
precipitate
pressure
probability of an event being due to chance alone
proline
protein-bound iodine (plasma)
pulmonary capillary blood flow
pyrophosphate (inorganic)
radiation dose; J/absorbed/g of material
red blood cell
red cell mass
relative band speed (partition chromatography)
rem
renin
residual volume
resistance (rheological)
respiratory exchange ratio (pulmonary)
respiratory quotient (metabolic)
revolutions
rev./min
ribonucleic acid
röntgen
saturation
second (time)
serine
sievert
solvent systems
species
specific activity

specific conductance of airways
standard deviation
standard error of the mean
standard temperature and pressure
steroid nomenclature
sulphydryl
sum
Svedberg unit
temperature (absolute)
temperature, thermodynamic	hin-layer chromatography
threonine
thyrotrophic hormone
thyrotrophin-releasing hormone
tidal volume
time (symbol)
time of day

total lung capacity
tryptophan
tubular maximal reabsorptive capacity for x
tyrosine
ultraviolet

urinary concentration of x
valine
variance ratio
vascular resistance

velocity
venous admixture
veronal

viscosity, dynamic
viscosity, kinematic
vital capacity
volt

volume of blood (in cardiorespiratory physiology)
watt
wavelength
weight
white blood cell

W (1 W = 0.1635 kpm/min)

P; express in kPa (except for blood pressures and gas tensions: see p. 6)
1 kPa = 7.5 mm Hg

P

Pro
PBI

PPI

use erythrocyte; express counts as \(10^7\) cells/l

RCM

100 ergs/g \times \text{quality factor}

see plasma renin activity

RV

R; express in kPa l\(^{-1}\) s

R

RQ

rev.

not r.p.m.; use g if possible (see p. viii)

RNA

R

S, e.g. \(S_a, O_2\) for arterial oxygen saturation

(value for other analogous abbreviations)

\(s\)

Ser

Sv (1 J/kg \times \text{quality factor})

e.g. butanol/acetic acid/water (4:1:1, by vol.), butanol/acetic acid (4:1, v/v)

sp., plural spp.

sp. act. Confusion must be avoided between e.g. specific radioactivity and the specific activity of an enzyme

sGaw; express in s\(^{-1}\) kPa\(^{-1}\)

\(\text{SD}\)

\(\text{SEM}\)

STP

see Biochemical Journal (1969) 113, 5-28; (1972) 127, 613-617

use thiol or SH

\(\Sigma\)

\(S\)

\(T\)

\(t\)

\(\circ K\)

t.l.c.

Thr

TSH

TRH

\(\nu_r\)

\(t\)

e.g. 18.15 hours

not used; use kPa (1 torr = 0.133 kPa)

TLC

Trp

Tm, x

Tyr

u.v.

e.g. Fe\(^{3+}\), not Fe\(^{++}\)

Val

F

express in kPa l\(^{-1}\) s (with
value in dyne cm s\(^{-1}\) in parentheses);
primary values of differential vascular pressure (mmHg) and
flow (l/min) should always also be given
in Tables or text as appropriate

\(w_1\)

express as m s\(^{-1}\)

\(\dot{Q}_v\)

used only for buffer mixtures; otherwise use
5,5'-diethylbarbituric acid

\(\eta\)

\(v\)

VC

\(V\)

\(\dot{Q}\); use \(\dot{Q}\) for blood flow rate

W

\(\lambda\)

wt.

use leucocyte; express counts as \(10^9\) cells/l
CONTENTS

VOL. 58, No. 1

JANUARY 1980

Guidance for Authors

Vasodepressor property of the converting enzyme inhibitor captopril (SQ 14 225): the role of factors other than renin-angiotensin blockade in the rat. E. S. MARKS, R. F. BING, H. THURSTON and J. D. SWALES

Modulation of the baroreceptor reflex by angiotensin II and other vasoactive drugs in anaesthetized greyhounds. J. D. MARKER, T. S. MILES and G. C. SCROOP

Response of chronic renovascular hypertension to surgical correction or prolonged blockade of the renin–angiotensin system by two inhibitors in the rat. H. THURSTON, R. F. BING, E. S. MARKS and J. D. SWALES

Baroreflex sensitivity in renal failure. O. TOMIYAMA, T. SHIGAI, T. IDEURA, K. TOMITA, Y. MITO, S. SHINOHARA and J. TAKEUCHI

Disappearance of angiotensin II and noradrenaline from the renal and femoral circulations of the dog. M. S. MILLER and G. C. SCROOP


Metabolism of vasoactive hormones in human isolated lung. F. Al-UBAIDI and Y. S. BAKHLE

Ultrasound measurements of pulse-wave velocity in the peripheral arteries of diabetic subjects. J. H. B. SCARPELLO, T. R. P. MARTIN and J. D. WARD

Peripheral resistance to the cellular action of insulin in obese diabetic subjects in vivo. J. P. D. RECKLESS and D. J. GALTON

Sieving studies in ‘urea-induced nephropathy’ in the dog. G. H. BEASTALL, W. S. WATSON and R. HUMBER

The effect of mineralocorticoid administration on urine free dopamine in man. N. S. OATES, C. M. PERKINS and M. R. LEE


Equilibration of tracer radioiron with body iron. R. W. CHARLTON, L. P. FATTI, S. R. LYNCH, J. D. TORRANCE and T. H. BOTHWELL

SHORT COMMUNICATIONS


Serum testosterone depression associated with hypoxia in respiratory failure. P. D'A. SEMPLE, G. H. BEASTALL, W. S. WATSON and R. HUME

Transport of lignocaine by rabbit choroid plexus in vitro. R. SPECTOR

The relationship between plasma biotin concentration and circulating leucocyte β-methyl-crotonyl-CoA carboxylase and propionyl-CoA carboxylase. K. BARTLETT, T. HORSBURGH and D. GOMPERTZ

The influence of physical activity on arterial pressure during ambulatory recording in man. D. B. ROWLANDS, T. J. STALLARD, R. D. S. WATSON and W. A. LITTLER

Acid–base changes after cardiorespiratory arrest in the dog. P. V. Greenwood, R. E. Rossall and C. T. Kappagoda 127–133

Growth hormone secretion in hypertensive patients: evidence for a derangement in central adrenergic function. C. Barbieri, C. Ferrari, R. Caldara and G. Curtarelli 135–138

Fate of vasopressin perfused into nephrons of Wistar and Brattleboro (diabetes insipidus) rats. M. D. Lindheimer, A. Reinhart, A. Grandchamp and M. B. Vallotton 139–144

Serum inorganic fluoride: changes related to previous fluoride intake, renal function and bone resorption. Christine Waterhouse, D. Taves and A. Munzer 145–152


Creatine kinase-1 is principally inactivated in serum by complexing with immunoglobulin-G. D. A. Nealon and A. R. Henderson 157–160

An association between plasma progesterone and erythrocyte carbonic anhydrase I concentration in women. J. Paciorek and N. Spencer 161–164

Short Communications

Characterization of the storage material of peripheral lymphocytes in aspartylglycosaminuria. P. Maury and J. Palo 165–168


Erythrocyte superoxide dismutase activity in Fanconi's anaemia. S. Okahata, Y. Kobayashi and T. Usui 173–175

Correspondence Section

Further studies on bone blood flow and age in the rat. P. Tothill and J. N. MacPherson 177–178

Salivary ethanol. B. M. Wright 178–179

Correlation of ethanol concentrations in blood and saliva. J. P. Royston 179–181

Medical Research Society (Meeting on 7 and 8 December 1979 Communications 1P–32P

Vol. 58, No. 3 March 1980


Cardiovascular responses to graded reductions of central blood volume in normal subjects and in patients with diabetes mellitus. T. Bennett, D. J. Hosking and J. R. Hampton 193–200
Contents

Prostaglandins as mediators of bone resorption in renal and breast tumours. M. GREAVES, K. J. IBBOTSON, D. ATKINS and T. J. MARTIN 201–210

Activities of some free-radical scavenging enzymes and glutathione concentrations in human and rat liver and their relationship to the pathogenesis of tissue damage in iron overload. CLARE SELDEN, CAROL A. SEYMOUR and T. J. PETERS 211–219

Influx of glycylsarcosine and L-lysyl-L-lysine into hamster jejunum in vitro. E. TAYLOR, D. BURSTON and D. M. MATTHEWS 221–225


Assessment of plasma 25-hydroxyvitamin D response to ultraviolet irradiation over a controlled area in young and elderly subjects. M. DAVIE and D. E. M. LAWSON 235–242


Practical importance of a preceding full inhalation or exhalation upon the measurement of airway resistance. T. HIGENBOTTAM and T. J. H. CLARK 249–253

SHORT COMMUNICATIONS


Sialic acid and the microheterogeneity of human serum ferritin. S. J. CRAgg, M. WAGSTAFF and M. WORWOOD 259–262

VOL. 58, NO. 4  APRIL 1980

Estimation of cardiac output from the rate of change of alveolar carbon dioxide pressure during rebreathing. MARY WINSBOROUGH, J. N. MILLER, D. W. BURGESS and G. LASZLO 263–270

Cardiogenic hypertension: experimental evidence from a comparison between intravenous and intracoronary administration of dobutamine in conscious dogs. J.-F. LIARD 271–277


The relative merits of various techniques for measuring radiocalcium absorption. R. WOOTTON and J. REEVE 287–293

Monocytes in inflammatory bowel disease: monocyte and serum lysosomal enzyme activity. A. S. MEE and D. P. JEWELL 295–300

Relationship between the basal blood alanine concentration and the removal of an alanine load in various clinical states in man. M. ELIA, VERA ILIC, SUSAN BACON, D. H. WILLIAMSON and R. SMITH 301–309

Urinary conjugates of 4-hydroxy-3-methoxyphenylethylene glycol do not provide an index of brain amine turnover in man. A. R. BOOBIS, S. MURRAY, D. H. JONES, J. L. REID and D. S. DAVIES 311–316

Lack of effect of somatostatin on iodothyronine release from the perfused canine thyroid. P. LAURBERG 317–320

Creatinine metabolism in chronic renal failure. W. E. MITCH, V. U. COLLIER and M. WALSER 327–335

SHORT COMMUNICATIONS


Editorial Review: Control of the pattern of breathing. H. GAUTIER 343–348


Parathyroid hormone- and deoxycorticosterone acetate-induced hypertension in the rat. A. BERTHELOT and A. GAIRARD 365–371


Renal metabolism of paracetamol: studies in the isolated perfused rat kidney. SANDRA HART, I. CALDER, B. ROSS and J. TANGE 379–384

Basal activity of the natriuretic factor extracted from the rat kidney as a function of the diet and its role in the regulation of the acute sodium balance. F. LOUIS and H. FAVRE 385–391

The role of prostaglandins in glucagon-induced natriuresis. M. A. KIRSCHENBAUM and E. T. ZAWADA 393–401

The induction of lysosomal enzyme release from leucocytes of normal and emphysematous subjects and the effects of tobacco smoke upon phagocytosis. D. C. S. HUTCHISON, R. DESAI, D. BELLAMY and H. BAUM 403–409

SHORT COMMUNICATIONS

Heart-rate changes on standing in elderly patients with orthostatic hypotension. N. J. WHITE 411–413

Insulin-induced renin release: blockade by indomethacin in the rat. W. B. CAMPBELL and JUDITH A. ZIMMER 415–418


Contents

Impaired intestinal absorption of dipeptide in tropical sprue patients in India. M. D. HELLIER, V. GANAPATHY, A. GAMMON, V. I. MATHAN and A. N. RADHAKRISHNAN 431–433


VOL. 58, NO. 6 JUNE 1980


The effect of captopril on blood pressure and angiotensins I, II and III in sodium-depleted dogs: problems associated with the measurement of angiotensin II after inhibition of converting enzyme. J. J. MORTON, M. TREE and J. CASALS-STENZEL 445–450

Preliminary evidence for the conversion of dog renin into a higher-molecular-weight form by cold storage. M. KAWAMURA, F. IKEMOTO and K. YAMAMOTO 451–456

Human lung adrenoreceptors studied by radioligand binding. P. J. BARNES, J. S. KARLINER and C. T. DOLLERY 457–461

Cyclic nucleotide excretion in human malignancies. N. H. HUNT, B. SMITH and R. PEMBREY 463–467

Urine concentration of 3-ethyl-5-hydroxy-4,5-dimethyl-Δ3-pyrroline-2-one (‘mauve factor’) is not causally related to schizophrenia or to acute intermittent porphyria. A. GORCHEIN 469–476

Identification of two types of porphyria cutanea tarda by measurement of erythrocyte uroporphyrinogen decarboxylase. G. H. ELDER, DIANE M. SHEPPARD, R. E. DE SALAMANCA and A. OLMOS 477–484

Determination of the pool size and synthesis rate of bile acids by measurements in blood of patients with liver disease. L. R. ENGELKING, S. BARNES, B. I. HIRSCHOWITZ, C. A. DASHER, J. G. SPENNERY and D. NAFTEL 485–492


The metabolism of a physiological dose of radioactive cholecalciferol (vitamin D3) to its hydroxylated metabolites in man. S. W. STANBURY and E. BARBARA MAWER 523–535

Histamine receptors in normal human bronchi. NOEMI M. EISER, JANE MILLS, K. D. MCRAE, P. D. SNASHALL and A. GUZ 537–544

SHORT COMMUNICATIONS

Effect of phalloidin on biliary lipid secretion in rats MARTA DUBIN and S. ERLINGER 545–548
Contents

The effects of the antagonists of the renin–angiotensin system on cardiovascular response to lower-body subatmospheric pressure in the anaesthetized cat. S. A. ADIGUN, D. P. CLOUGH, J. CONWAY and R. HATTON 549–552

Effect of aging on energy-rich phosphagens in human skeletal muscles. P. MÖLLER, J. BERGSTROM, P. FÜRST and K. HELLSTRÖM 553–555